[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341548-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341548-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-vi-rads-scoring-criteria-for-predicting-oncological-outcomes-in-bladder-cancer","The role of VI-RADS scoring criteria for predicting oncological outcomes in bladder cancer","","Purpose was to evaluate the prognostic value of Vesical Imaging Reporting and Data System (VI-RADS) for bladder cancer staging and for predicting recurrence or progression. Methods retrospectively analyzed prospectively collected data from 96 patients who underwent VI-RADS-based multiparametric MRI before endourological treatment, comparing MRI reports with final pathology and applying logistic regression plus Kaplan-Meier and Cox analyses during follow-up to May 2023. Results showed high sensitivity and specificity for muscle-invasive prediction, with VI-RADS ≥3 linked to shorter RFS and PFS. Conclusions support mpMRI with VI-RADS as a strong predictive tool for MIBC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-vi-rads-scoring-criteria-for-predicting-oncological-outcomes-in-bladder-cancer/341548/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-vi-rads-scoring-criteria-for-predicting-oncological-outcomes-in-bladder-cancer/341548.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary purpose of the study?","Question",{"text":63,"@type":64},"To evaluate the prognostic value of VI-RADS for bladder cancer staging and for predicting recurrence or progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected for the analysis?",{"text":68,"@type":64},"Ninety-six patients with bladder tumors underwent VI-RADS-based 1.5-Tesla multiparametric MRI before TURBT, with eligibility and exclusions based on criteria related to renal function, contrast contraindications, mpMRI safety, consent, prior treatment, and other malignancies affecting bladder assessment.",{"name":70,"@type":61,"acceptedAnswer":71},"What VI-RADS threshold was associated with worse outcomes?",{"text":72,"@type":64},"Primary tumors with VI-RADS ≥3 demonstrated significantly shorter recurrence-free survival (RFS) and progression-free survival (PFS).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341548,1790812442,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","World Journal of Urology (2024) 42:438  \n[https://doi.org/10.1007/s00345-024-05101-2](https://doi.org/10.1007/s00345-024-05101-2)  \nORIGINAL ARTICLE  \nThe role of VI-RADS scoring criteria for predicting oncological outcomes in bladder cancer  \nMieszko Kozikowski1,2,3,4 · Magdalena Zagrodzka2 · Marek Zawadzki1,3 · Przemysław Zugaj1 · Rafał Osiecki6 · Franciszek Rzymkowski2 · Mateusz Śledź2 · Roman Sosnowski4,5 · Jakub Dobruch6 · Francesco Del Giudice7 · Wojciech Krajewski4,8  \nReceived: 8 March 2024 / Accepted: 31 May 2024 © The Author(s) 2024  \nAbstract  \nPurpose Our purpose was to evaluate the prognostic value of Vesical Imaging Reporting and Data System (VI-RADS) in bladder cancer (BCa) staging and predicting recurrence or progression.  \nMethods We retrospectively analyzed the prospectively collected data from 96 patients with bladder tumors who underwent VI-RADS-based multiparametric magnetic resonance imaging (mpMRI) before endourological treatment from April 2021 to December 2022. Diagnostic performance was evaluated by comparing mpMRI reports with final pathology, using logistic regression for muscle-invasive bladder cancer (MIBC) predictors. Follow-up until May 2023 included Kaplan-Meier and Cox regression analysis to assess VI-RADS predictive roles for recurrence-free survival (RFS) and progression-free survival (PFS) .  \nResults A total of 96 patients (19.8% women, 80.2% men; median age 68.0 years) were included, with 71% having primary tumors and 29% recurrent BCa. Multiparametric MRI exhibited high sensitivity (92%) and specificity (79%) in predicting MIBC, showing no significant differences between primary and recurrent cancers (AUC: 0.96 vs. 0.92, P = .565) . VI-RADS emerged as a key predictor for MIBC in both univariate (OR: 40.3, P \u003C .001) and multivariate (OR: 54.6, P \u003C .001) analyses. Primary tumors with VI-RADS ≥3 demonstrated significantly shorter RFS (P = .02) and PFS (P = .04) .  \nConclusions In conclusion, mpMRI with VI-RADS has a high diagnostic value in predicting MIBC in both primary andrecurrent BCa. A VI-RADS threshold ≥3 is a strong predictor for MIBC, and in primary tumors predicts early recurrence and progression.  \nKeywords Bladder cancer · Multiparametric magnetic resonance imaging · Recurrence · Bladder cancer staging  \n􀀍 Mieszko Kozikowski [mieszkokozikowski9@gmail.com](mieszkokozikowski9@gmail.com)  \n1 Polish Center of Advanced Urology, Department of Urology, St. Anne’s Hospital EMC, Piaseczno, Poland  \n2 Department of Diagnostic Imaging-Quadia, Piaseczno, Poland  \n3 Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland  \n4 Section of Urologic Oncology of Polish Urological Association, Warsaw, Poland  \n5 Department of Urology and Oncological Urology, WarmianMasurian Cancer Center, Olsztyn, Poland  \n6 Urology Clinic of Medical Postgraduate Education Centre, Department of Urology, Independent Public Hospital them. prof. W. Orlowski, Warsaw, Poland  \n7 Department of Maternal Infant and Urologic Sciences,“Sapienza” University of Rome, Policlinico Umberto I Hospital, Rome, Italy  \n8 Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland  \n1 3  \nIntroduction  \nBladder cancer (BCa) ranks as the fourth most common malignancy in men and the fourth leading cause of cancerrelated deaths in old age [1] . Accurate staging is crucial for therapeutic decisions in BCa patients, as non-muscleinvasive bladder cancer (NMIBC) carries a different prognosis and necessitates distinct treatment options compared to muscle-invasive bladder cancer (MIBC) [2] . NMIBC accounts for approximately 75% of BCa cases, posing a significant challenge in predicting disease recurrence and progression [3] . The risk of NMIBC progressing to MIBC within 5 years after primary transurethral resection of the bladder tumor (TURBT) varies widely, from less than 1% to over 40% among risk groups, influencing treatment choi","cbCaibz7X7NU9JsN","https://ap.wps.com/l/cbCaibz7X7NU9JsN","pdf",912930,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Clinical need for accurate bladder cancer staging\n## Role of mpMRI and VI-RADS\n# Materials and methods\n## Patients and study design\n## Outcomes and analysis approach","[{\"question\":\"What was the primary purpose of the study?\",\"answer\":\"To evaluate the prognostic value of VI-RADS for bladder cancer staging and for predicting recurrence or progression.\"},{\"question\":\"How were patients selected for the analysis?\",\"answer\":\"Ninety-six patients with bladder tumors underwent VI-RADS-based 1.5-Tesla multiparametric MRI before TURBT, with eligibility and exclusions based on criteria related to renal function, contrast contraindications, mpMRI safety, consent, prior treatment, and other malignancies affecting bladder assessment.\"},{\"question\":\"What VI-RADS threshold was associated with worse outcomes?\",\"answer\":\"Primary tumors with VI-RADS ≥3 demonstrated significantly shorter recurrence-free survival (RFS) and progression-free survival (PFS).\"}]","The role of VI-RADS scoring criteria for predicting oncological outcomes in bladder cancer | PDF",1790042503,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abd7916ef72d231bd7f2f77467470453.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ab94f791a075161987864e3f2c854bb.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/189609699da6205a8ee0ed20fbc14bfc.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2322a99039ba4afb4a3c7251a781eaf9.webp",980,1301]